The WACC of Arecor Therapeutics PLC (AREC.L) is 10.9%.
| Range | Selected | |
| Cost of equity | 9.60% - 12.40% | 11.00% |
| Tax rate | 8.30% - 11.60% | 9.95% |
| Cost of debt | 6.20% - 7.00% | 6.60% |
| WACC | 9.5% - 12.3% | 10.9% |
| Category | Low | High |
| Long-term bond rate | 4.0% | 4.5% |
| Equity market risk premium | 6.0% | 7.0% |
| Adjusted beta | 0.93 | 1.06 |
| Additional risk adjustments | 0.0% | 0.5% |
| Cost of equity | 9.60% | 12.40% |
| Tax rate | 8.30% | 11.60% |
| Debt/Equity ratio | 0.01 | 0.01 |
| Cost of debt | 6.20% | 7.00% |
| After-tax WACC | 9.5% | 12.3% |
| Selected WACC | 10.9% | |
The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.
This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.
Here’s how we figure out the cost of equity for AREC.L:
cost_of_equity (11.00%) = risk_free_rate (4.25%) + equity_risk_premium (6.50%) * adjusted_beta (0.93) + risk_adjustments (0.25%)
We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.